Suggested Reading
Bang YJ, Van Custem E, Feyereislova A, et al: Trastuzumab(Drug information on trastuzumab) in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010.
Bang YJ, Kim YW, Yang HK, et al: Adjuvant capecitabine(Drug information on capecitabine) and oxaliplatin(Drug information on oxaliplatin) for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet 379:315-321, 2012.
Becker K, Langer R, Reim D, et al: Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: A summary of 480 cases. Ann Surg 253:934-939, 2011.
Chen Y, Kingham K, Ford JM, et al: A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Ann Surg Oncol 8:2594-2598, 2011.
Dematteo RP, Ballman KV, Antonescu CR, et al: Adjuvant imatinib(Drug information on imatinib) mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 373:1097-1104, 2009.
Dikken JL, Jansen EP, Cats A, et al: Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 28:2430-2436, 2010.
Dudeja V, Gay G, Habermann EB, et al: Do hospital attributes predict guideline-recommended gastric cancer care in the United States? Ann Surg Oncol 19:365-372, 2012.
Koizumi W, Narahara, H, Hara, T et al: S-1 plus cisplatin(Drug information on cisplatin) versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 9:215-221, 2008.
Okines AF, Norman AR, McCloud P: Meta-analysis of the REAL-2 and ML17032 trials: Evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 20:1529-1534, 2009.
Song J, Lee HJ, Cho GS, et al: Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: A multicenter retrospective analysis of 1,417 patients. Ann Surg Oncol 17:1777-1786, 2010.
Songun I, Putter H, Kranenbarg EM, et al: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439-449, 2010.
Stahl M, Walz MK, Stuschke M, et al: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851-856, 2009.
Joensuu H, Eriksson M, Sundby HK, et al: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 307:1265-1272, 2012.
Joensuu H, Vehtari A, Riihimaki J, et al: Risk of recurrence of gastrointestinal stromal tumour after surgery: An analysis of pooled population-based cohorts. Lancet Oncol 13:265-274, 2012.
Lee J, Lim do H, Kim S, et al: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268-273, 2012.
Wang J, Dang P, Raut CP, et al: Comparison of a lymph node ratio-based staging system with the 7th AJCC system for gastric cancer: Analysis of 18,043 patients from the SEER database. Ann Surg 255:478-485, 2012.
Smalley SR, Benedetti JK, Haller DG, et al: Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327-2333, 2012.
Ohtsu A, Shah MA, Van Cutsem E, et al: Bevacizumab(Drug information on bevacizumab) in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968-3976, 2011.
